NGR-TNF

Drug Profile

NGR-TNF

Alternative Names: ARENEGYR; CNGRC peptide-TNF alpha conjugate; NGR-hTNF; NGR-TNFα; Zafiride

Latest Information Update: 07 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Scientific Institute San Raffaele
  • Developer European Organisation for Research and Treatment of Cancer; MolMed; Scientific Institute San Raffaele
  • Class Antineoplastics; Recombinant fusion proteins
  • Mechanism of Action Capillary permeability modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma; Mesothelioma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Mesothelioma
  • Phase II Colorectal cancer; Hepatocellular carcinoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer; Soft tissue sarcoma
  • No development reported Solid tumours

Most Recent Events

  • 04 Jun 2018 Efficacy and safety data from a phase II INGRID trial in Non-Hodgkin's lymphoma released by MolMed
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy) in Italy (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease) in Italy (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top